

12/28/99 ***This is a representation of the official roadmap.***

***All errors are mine -- BBP***

OSTEOSARCOMA OUTCOME OF THERAPY BASED ON HISTOLOGIC RESPONSE

**ROADMAP – All Patients**

NAME: \_\_\_\_\_ MR#: \_\_\_\_\_

Ht: \_\_\_\_\_ (cm) Wt: \_\_\_\_\_ (kg) BSA: \_\_\_\_\_

**PRE STUDY:** History/Physical; CBC/diff/plts: Lytes, BUN, Cr, Ca, Mg, PO4, ALT/AST, Bili, Alk phos LDH; UA; Echo/Muga Audiogram; X-Rays of primary site + chest; CT chest; Bone Scan; MRI primary incl. Joints proximal & distal; GFR scan; Biopsy + tissue for biologic studies; Central line placement;

WEEK	DAY DUE	DATE DONE	DATE	AGENT/DOSE	STUDIES/ACTION
0	1	_____	_____	Cisplatin _____mg Doxorubicin _____mg Dexrazoxane _____mg	pre-study labs as above
	2	_____	_____	Cisplatin _____mg Doxorubicin _____mg Dexrazoxane _____mg	
	3	_____	_____	G-CSF _____mg	
1		_____			
2		_____			
3	1	_____	_____	Methotrexate _____mg	H&P; CBCD/p, Lytes, Cr, Ca, Mg, PO4, ALT/AST, Bili, Alk phos, LDH
4	1	_____	_____	Methotrexate _____mg	H&P; CBCD/p, Lytes, Cr, Ca, Mg, PO4, ALT/AST, Bili, Alk phos, LDH
5	1	_____	_____	Cisplatin _____mg Doxorubicin _____mg Dexrazoxane _____mg	H&P; CBCD/p, Lytes, Cr, Ca, Mg, PO4, ALT/AST, Bili, Alk phos, LDH
	2	_____	_____	Cisplatin _____mg Doxorubicin _____mg Dexrazoxane _____mg	
	3	_____	_____	G-CSF _____mg	

OSTEOSARCOMA OUTCOME OF THERAPY BASED ON HISTOLOGIC RESPONSE**ROADMAP – All Patients**

NAME: \_\_\_\_\_ MR#: \_\_\_\_\_

WEEK	DAY DUE	DATE DONE	DATE	AGENT/DOSE	STUDIES/ACTION
6	1	_____	_____		
7		_____			
8	1	_____	_____	Methotrexate _____mg	H&P; CBCD/p, Lytes, Cr, Ca. Mg, PO4, ALT/AST, Bili, Alk phos, LDH
9	1	_____	_____	Methotrexate _____mg	H&P; CBCD/p, Lytes, Cr, Ca. Mg, PO4, ALT/AST, Bili, Alk phos, LDH
10	1	_____			H&P; CBCD/p.; ALT/AST; Bili, Alk phos, LDH; X-ray of 1 <sup>0</sup> site and chest, Bone Scan, CT chest, MRI of primary incl. Joints proximal & distal; GFR, Audiogram
11	1	_____			Surgery of 1 <sup>0</sup> site. Surgery for mets when feasible. Send tissue for CGAP studies.
12		_____			
13		_____			

***Obtain other studies as required for good patient care***

Patients with histologic response of  $\geq 98\%$  necrosis will continue therapy with cisplatin (2 courses), Doxorubicin (4 courses) and Methotrexate (8 courses).

Patients with histologic response of  $< 98\%$  necrosis will undergo peripheral stem cell harvest and be treated with 3 courses cyclophosphamide and melphalan with peripheral stem cell support.

Patients with unresectable primary or those with metastases at diagnosis will undergo peripheral stem cell harvest during the recovery phase following the first or second course of cisplatin and doxorubicin chemotherapy of the neoadjuvant phase prior to definitive surgery.

***This is a representation of the official roadmap.  
All errors are mine - BBP***